Literature DB >> 3261062

Disposition in male volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of 14C-propofol.

P J Simons1, I D Cockshott, E J Douglas, E A Gordon, K Hopkins, M Rowland.   

Abstract

1. An intravenous dose of 14C-propofol (0.47 mg/kg) administered to six male volunteers was rapidly eliminated with 88% recovered in the urine in 5 days and less than 2% in faeces. 2. The dose was cleared by metabolism with less than 0.3% excreted unchanged. The major metabolites were the glucuronic acid conjugate of propofol and the glucuronic acid and sulphate conjugates of its hydroxylated derivative, 2,6-diisopropyl-1,4-quinol. Propofol glucuronide accounted for about 53% of the urinary radioactivity and was the major metabolite in plasma from 30 min post dose. 3. The blood concentration of propofol declined in a biphasic manner from a maximum mean value of 0.44 microgram/ml, 2 min after injection. The half-lives of the first and second exponential phases, mean values 5 min and 97 min respectively, varied widely among subjects. A proportion of the dose was cleared slowly, probably due to slow release from less well perfused tissues. Propofol accounted for 94% of the total blood radioactivity at 2 min but only about 6% from 3 to 8 h post dose. 4. Propofol has a volume of distribution equivalent to about 3 to 4 times body weight, and a mean total body clearance of 2.2 1/min.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261062     DOI: 10.3109/00498258809041679

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  35 in total

1.  Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia.

Authors:  Irena Loryan; Marja Lindqvist; Inger Johansson; Masahiro Hiratsuka; Ilse van der Heiden; Ron H N van Schaik; Jan Jakobsson; Magnus Ingelman-Sundberg
Journal:  Eur J Clin Pharmacol       Date:  2011-10-18       Impact factor: 2.953

2.  Pharmacokinetics of propofol when given by intravenous infusion.

Authors:  D J Morgan; G A Campbell; D P Crankshaw
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

Review 3.  Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm.

Authors:  Derek J Roberts; Babar Haroon; Richard I Hall
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546

Review 4.  Propofol: a review of its role in pediatric anesthesia and sedation.

Authors:  Vidya Chidambaran; Andrew Costandi; Ajay D'Mello
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

5.  Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain.

Authors:  Haruhiko Hiraoka; Koujirou Yamamoto; Soutarou Miyoshi; Toshihiro Morita; Katsunori Nakamura; Yuuji Kadoi; Fumio Kunimoto; Ryuya Horiuchi
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

6.  Cosegregation of intragenic markers with a novel mutation that causes Crigler-Najjar syndrome type I: implication in carrier detection and prenatal diagnosis.

Authors:  N Moghrabi; D J Clarke; B Burchell; M Boxer
Journal:  Am J Hum Genet       Date:  1993-09       Impact factor: 11.025

Review 7.  Propofol in patients with cardiac disease.

Authors:  N R Searle; P Sahab
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

8.  A Rare Case of Propofol-Induced Acute Liver Failure and Literature Review.

Authors:  G Kneiseler; H S Bachmann; L P Bechmann; A Dechene; T Heyer; H Baba; F Saner; C Jochum; G Gerken; A Canbay
Journal:  Case Rep Gastroenterol       Date:  2010-02-06

9.  Premedication medicines do not cause drug metabolic interaction with propofol using human liver microsomes in vitro.

Authors:  Einosuke Tanaka; Yui Takano; Shinichi Inomata; Hidenori Toyooka; Katsuya Honda
Journal:  Eur J Clin Pharmacol       Date:  2004-09-04       Impact factor: 2.953

10.  In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine.

Authors:  Sam Boase; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.